Enwei Pharmaceutical Co., Ltd.

301331

CNE100005LC7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 17/07/2024 am IST			5-day change	1st Jan Change
21.71 ^CNY	-0.41%		-1.54%	-22.60%

02/07	Tranche Update on Enwei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 21, 2023.	CI
14/05	Enwei Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023	CI

Tranche Update on Enwei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 21, 2023.

July 03, 2024 at 01:11 am IST

From April 1, 2024 to June 30, 2024, the company has repurchased 1,108,872 shares, representing 1.08% for CNY 36.87 million. With this, the company has completed the repurchase of 3,010,713 shares, representing 2.92% for CNY 110.43 million under the buyback announced on October 21, 2023.

Latest news about Enwei Pharmaceutical Co., Ltd.

Tranche Update on Enwei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 21, 2023.	03/07	CI
Enwei Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023	15/05	CI
Enwei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	21/04	CI
Tranche Update on Enwei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 21, 2023.	02/04	CI
Enwei Pharmaceutical Co., Ltd. Approves Appointment of Independent Directors and Non-Employee Supervisors	31/01	CI
Tranche Update on Enwei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 21, 2023.	02/01	CI
Enwei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	26/23/26	CI
Enwei Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 150 million worth of its shares.	20/23/20	CI
Enwei Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	20/23/20	CI
Certain A Shares of Enwei Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 20-SEP-2023.	20/23/20	CI
Enwei Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	27/23/27	CI
Enwei Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 23 May 2023	17/23/17	CI
Enwei Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2022	16/23/16	CI
Enwei Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2022	25/23/25	CI
Enwei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	21/23/21	CI
Enwei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	26/22/26	CI
Enwei Pharmaceutical Co., Ltd. has completed an IPO in the amount of CNY 522.692 million.	08/22/08	CI

Chart Enwei Pharmaceutical Co., Ltd.

Duration

Period

More charts

Company Profile

Enwei Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of proprietary Chinese medicines and chemical medicines. The Company focuses on gynecological products, pediatric medicines, respiratory medicines and other fields. The Company's main products include Jieeryin lotion, Jieeryin ointment, Jieeryin effervescent tablets, Shanmai Jianpi oral liquid, Qingjing capsules and Danxiong Tongmai granules. Its products are mainly sold through direct sales and e-commerce. The Company principally conducts its businesses in the domestic market.

Sector

Pharmaceuticals

Calendar

30/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ENWEI PHARMACEUTICAL CO., LTD.	-22.60%	30Cr
ELI LILLY AND COMPANY	+55.35%	85TCr
NOVO NORDISK A/S	+31.64%	63TCr
JOHNSON & JOHNSON	-0.10%	36TCr
MERCK & CO., INC.	+15.47%	32TCr
ABBVIE INC.	+13.10%	30TCr
ASTRAZENECA PLC	+15.51%	24TCr
NOVARTIS AG	+16.72%	23TCr
AMGEN INC.	+16.54%	18TCr
PFIZER, INC.	+4.31%	17TCr